JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.

Dermatologica Sinica, published by Wolters Kluwer Medknow Publications, is an esteemed open-access journal in the field of dermatology that has been disseminating critical research since its inception in 2005. With an E-ISSN of 2223-330X and an ISSN of 1027-8117, this journal presents a platform for researchers, clinicians, and students to share cutting-edge findings and advancements in dermatological science. As of 2023, it proudly ranks in the Q2 category of dermatology journals and holds a notable position at rank #62 out of 142 in the Scopus Medicine - Dermatology category, placing it in the 56th percentile for impact. The journal transitioned to an open-access model in 2016, enhancing accessibility and visibility for groundbreaking studies worldwide. With a commitment to fostering innovation in the dermatological community, Dermatologica Sinica aims to advance the understanding and treatment of skin diseases while encouraging scholarly dialogue among practitioners and researchers across the globe.

Acta Naturae is a peer-reviewed scientific journal published by the Russian Federation Agency for Science & Innovation, focusing on the dynamic fields of Biochemistry, Biotechnology, Molecular Biology, and Molecular Medicine. Launched in 2013, the journal has established a solid reputation in the academic community, with its articles contributing to essential advancements and discussions within these disciplines. By 2023, it has achieved notable rankings—including Q2 status in Biotechnology and Q3 in Biochemistry, Molecular Biology, and Molecular Medicine—indicating its growing influence and relevance in the scientific literature. While currently operating under a non-open access model, Acta Naturae invites researchers, professionals, and students to engage with its comprehensive research reports and reviews that span the breadth of molecular life sciences. With the aim of facilitating scientific dialogue and innovation, this journal serves as a key resource for those seeking to stay at the forefront of molecular research.

Cancer Causes & Control, an esteemed journal within the field of Cancer Research and Oncology, is published by SPRINGER. Since its inception in 1990, this journal has dedicated itself to exploring the complex interplay between environmental, genetic, and lifestyle factors that contribute to cancer causation and control, aiming to inform public health initiatives and improve cancer prevention strategies. With an impressive Q2 rank in both its categories, the journal serves as a vital resource for researchers, professionals, and students seeking insights into the latest findings and methodologies in cancer epidemiology. Although there is no Open Access option, researchers can access valuable articles that reflect rigorous peer review and significant contributions to the field. The journal’s commitment to advancing knowledge related to cancer risks and management makes it an essential platform for disseminating impactful research and fostering collaboration among scholars worldwide.

Middle East Journal of Cancer, with an ISSN of 2008-6709 and an E-ISSN of 2008-6687, is a prominent open-access journal published by Shiraz University of Medical Sciences since 2010. Based in Iran, the journal aims to advance the knowledge and understanding of cancer research and oncology through the dissemination of high-quality, peer-reviewed articles. With open access availability, it promotes global collaboration and accessibility in research, making findings readily available to a wider audience. The journal is categorized in Q4 for both Cancer Research and Oncology as of 2023, highlighting its emerging presence in these fields. Alongside its Scopus ranks, where it positions 319th out of 404 in Medicine - Oncology and 198th out of 230 in Biochemistry, Genetics and Molecular Biology - Cancer Research, it serves as a platform for researchers, professionals, and students to enrich their expertise and contribute to the evolving landscape of cancer studies. The journal's continuous commitment to quality and accessibility represents an essential resource for those dedicated to advancing cancer research and improving patient outcomes in the Middle East and beyond.